Literature DB >> 16534707

Structural allografts for bone stock reconstruction in two-stage revision for infected total hip arthroplasty: good outcome in 16 of 18 patients followed for 5-14 years.

Iulian Nusem1, David A F Morgan.   

Abstract

BACKGROUND: The use of massive bone allografts in cases of revision of failed total hip arthroplasties (THAs) due to infection is controversial. PATIENTS AND METHODS: 18 patients presented with infection at the site of a THA and were treated with a two-stage protocol. In the first stage, the prosthesis was removed together with all necrotic tissues and cement material if present. A custom-made mold of Palacos R cement containing 1 g of gentamicin was then inserted in 17 of the 18 patients. Systemic antibiotics were used during the interval period. In the second stage, the patients had either acetabular or femoral reconstruction using bulk allograft bone.
RESULTS: Mean follow-up was 9 (5-14) years. 1 patient presented with recurrent infection and underwent a Girdlestone resection arthroplasty as definitive treatment. Another patient had a mechanical failure of the acetabular component, which was revised 10 years after the second stage of the reconstruction. The mean Harris Hip Score improved from 34 points preoperatively to 71 points at the last review. By our definition, 16/18 of the patients had a successful outcome.
INTERPRETATION: Our results support the use of massive allografts in staged reconstructions of infected THAs complicated by considerable bone loss.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534707     DOI: 10.1080/17453670610045740

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  8 in total

1.  Partial two-stage exchange for infected total hip arthroplasty: a preliminary report.

Authors:  Timothy E Ekpo; Keith R Berend; Michael J Morris; Joanne B Adams; Adolph V Lombardi
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

2.  Structural allograft as an option for treating infected hip arthroplasty with massive bone loss.

Authors:  Paul T H Lee; Robert A Clayton; Oleg A Safir; David J Backstein; Allan E Gross
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

3.  Cementless two-staged total hip arthroplasty with a short term interval period for chronic deep periprosthetic infection. Technique and long-term results.

Authors:  Jochen Erhart; Karl Jaklitsch; Mark Schurz; Vilmos Vécsei; Reinhard Ehall
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

4.  Two-stage treatment of hip periprosthetic joint infection is associated with a high rate of infection control but high mortality.

Authors:  Keith R Berend; Adolph V Lombardi; Michael J Morris; Adam G Bergeson; Joanne B Adams; Michael A Sneller
Journal:  Clin Orthop Relat Res       Date:  2013-02       Impact factor: 4.176

5.  [Reconstruction of metadiaphyseal bone defects of the femur with cortical strut allografts in periprosthetic bone loss].

Authors:  G Orfanos; Y Ding; C P Bode; B Barden; J G Fitzek
Journal:  Oper Orthop Traumatol       Date:  2014-04-02       Impact factor: 1.154

6.  Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis.

Authors:  Jeppe Lange; Anders Troelsen; Reimar W Thomsen; Kjeld Søballe
Journal:  Clin Epidemiol       Date:  2012-03-27       Impact factor: 4.790

7.  Two-stage revision total hip arthroplasty for periprosthetic infections using antibiotic-impregnated cement spacers of various types and materials.

Authors:  Katsufumi Uchiyama; Naonobu Takahira; Kensuke Fukushima; Mitsutoshi Moriya; Takeaki Yamamoto; Yojiro Minegishi; Rina Sakai; Moritoshi Itoman; Masashi Takaso
Journal:  ScientificWorldJournal       Date:  2013-12-07

Review 8.  Does cemented or cementless single-stage exchange arthroplasty of chronic periprosthetic hip infections provide similar infection rates to a two-stage? A systematic review.

Authors:  D A George; N Logoluso; G Castellini; S Gianola; S Scarponi; F S Haddad; L Drago; C L Romano
Journal:  BMC Infect Dis       Date:  2016-10-10       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.